|
|
免疫检查点抑制剂在鼻咽癌治疗中的研究进展
|
Abstract:
鼻咽癌是最常见的头颈部肿瘤之一，发病与EB病毒密切相关，其标准治疗方式是同步放化疗，但是其复发和远处转移是造成鼻咽癌预后不佳的难题，随着免疫治疗在其他实体瘤中取得较大的进展，免疫检查点抑制剂也逐渐应用于鼻咽癌，并体现其临床价值，本文对免疫检查点抑制剂单药及联合化疗、靶向、放疗治疗复发或转移性鼻咽癌的研究进展进行综述。
Nasopharyngeal carcinoma is one of the most common head and neck tumors, and its incidence is closely related to EB virus. The standard treatment is concurrent radiotherapy and chemotherapy, but its recurrence and distant metastasis are the problems that cause poor prognosis of nasopharyngeal carcinoma. With the great progress of immunotherapy in other solid tumors, immune checkpoint inhibitors are gradually applied to nasopharyngeal carcinoma, which shows its clinical value. This article reviews the research progress of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma.
| [1] | Chen, Y.P., Chan, A.T.C., Le, Q.T., Blanchard, P., Sun, Y. and Ma, J. (2019) Nasopharyngeal Carcinoma. The Lancet, 394, 64-80. https://doi.org/10.1016/S0140-6736(19)30956-0 |
| [2] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [3] | Juarez-Vignon Whaley, J.J., Afkhami, M., Onyshchenko, M., Massarelli, E., Sampath, S., Amini, A., Bell, D. and Villaflor, V.M. (2023) Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading? Current Treatment Options in Oncology, 24, 1138-1166. https://doi.org/10.1007/s11864-023-01101-3 |
| [4] | Jalili-Nik, M., Soltani, A., Mashkani, B., Rafatpanah, H. and Hashemy, S.I. (2021) PD-1 and PD-L1 Inhibitors Foster the Progression of Adult T-Cell Leukemia/Lymphoma. International Immunopharmacology, 98, Article ID: 107870. https://doi.org/10.1016/j.intimp.2021.107870 |
| [5] | Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L. and Wang, S (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article 964442. https://doi.org/10.3389/fimmu.2022.964442 |
| [6] | Yang, Y., Li, X., Ma, Z., Wang, C., Yang, Q., Byrne-Steele, M., Hong, R., Min, Q., Zhou, G., Cheng, Y., et al. (2021) CTLA-4 Expression by B-1a B Cells Is Essential for Immune Tolerance. Nature Communications, 12, Article No. 525. https://doi.org/10.1038/s41467-020-20874-x |
| [7] | Hsu, C., Lee, S.H., Ejadi, S., Even, C., Cohen, R.B., Le Tourneau, C., Mehnert, J.M., Algazi, A., Van Brummelen, E.M.J., Saraf, S., et al. (2017) Safety and Antitumor Activity of Pembrolizumab in Patients with Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Journal of Clinical Oncology, 35, 4050-4056. https://doi.org/10.1200/JCO.2017.73.3675 |
| [8] | Huang, H., Yao, Y., Deng, X., Weng, H., Chen, Z., Yu, L., Wang, Z., Fang, X., Hong, H., Huang, H., et al. (2023) Characteristics of Immunotherapy Trials for Nasopharyngeal Carcinoma over a 15-Year Period. Frontiers in Immunology, 14, Article 1195659. https://doi.org/10.3389/fimmu.2023.1195659 |
| [9] | Chan, A.T.C., Lee, V.H.F., Hong, R.L., Ahn, M.J., Chong, W.Q., Kim, S.B., Ho, G.F., Caguioa, P.B., Ngamphaiboon, N., Ho, C., et al. (2023) Pembrolizumab Monotherapy versus Chemotherapy in Platinum-Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer (KEYNOTE-122): An Open-Label, Randomized, Phase III Trial. Annals of Oncology, 34, 251-261. https://doi.org/10.1016/j.annonc.2022.12.007 |
| [10] | Luo, J., Xiao, W., Hua, F., Cao, Y., Wang, D. and Wang, X. (2023) Efficacy and Safety of PD-1 Inhibitors in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients after Failure of Platinum-Containing Regimens: A Systematic Review and Meta-Analysis. BMC Cancer, 23, Article No. 1172. https://doi.org/10.1186/s12885-023-11318-y |
| [11] | Chen, C., Wang, F.H., An, X., Luo, H.Y., Wang, Z.Q., Liang, Y., Zhang, L. and Li, Y.H. (2013) Triplet Combination with Paclitaxel, Cisplatin and 5-FU Is Effective in Metastatic and/or Recurrent Nasopharyngeal Carcinoma. Cancer Chemotherapy and Pharmacology, 71, 371-378. https://doi.org/10.1007/s00280-012-2020-x |
| [12] | Wu, J. and Waxman, D.J. (2018) Immunogenic Chemotherapy: Dose and Schedule Dependence and Combination with Immunotherapy. Cancer Letters, 419, 210-221. https://doi.org/10.1016/j.canlet.2018.01.050 |
| [13] | Yang, Y., Pan, J., Wang, H., Zhao, Y., Qu, S., Chen, N., Chen, X., Sun, Y., He, X., Hu, C., et al. (2023) Tislelizumab plus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: A Multicenter Phase 3 Trial (RATIONALE-309). Cancer Cell, 41, 1061-1072.E4. https://doi.org/10.1016/j.ccell.2023.04.014 |
| [14] | Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., et al. (2021) Camrelizumab versus Placebo in Combination with Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN-1st): A Multicentre, Randomised, Double-Blind, Phase 3 Trial. The Lancet Oncology, 22, 1162-1174. https://doi.org/10.1016/S1470-2045(21)00302-8 |
| [15] | Mai, H.Q., Chen, Q.Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y.R., Jin, F., Xu, R., et al. (2021) Toripalimab or Placebo plus Chemotherapy as First-Line Treatment in Advanced Nasopharyngeal Carcinoma: A Multicenter Randomized Phase 3 Trial. Nature Medicine, 27, 1536-1543. https://doi.org/10.1038/s41591-021-01444-0 |
| [16] | Khan, K.A. and Kerbel, R.S. (2018) Improving Immunotherapy Outcomes with Anti-Angiogenic Treatments and Vice Versa. Nature Reviews Clinical Oncology, 15, 310-324. https://doi.org/10.1038/nrclinonc.2018.9 |
| [17] | Huinen, Z.R., Huijbers, E.J.M., Van Beijnum, J.R., Nowak-Sliwinska, P. and Griffioen, A.W. (2021) Anti-Angiogenic Agents-Overcoming Tumour Endothelial Cell Anergy and Improving Immunotherapy Outcomes. Nature Reviews Clinical Oncology, 18, 527-540. https://doi.org/10.1038/s41571-021-00496-y |
| [18] | Yap, T.A., Parkes, E.E., Peng, W., Moyers, J.T., Curran, M.A. and Tawbi, H.A. (2021) Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 11, 1368-1397. https://doi.org/10.1158/2159-8290.CD-20-1209 |
| [19] | Motzer, R.J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 380, 1103-1115. https://doi.org/10.1056/NEJMoa1816047 |
| [20] | Rini, B.I., Plimack, E.R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 380, 1116-1127. https://doi.org/10.1056/NEJMoa1816714 |
| [21] | Ackroyd, S.A., Huang, E.S., Kurnit, K.C. and Lee, N.K. (2021) Pembrolizumab and Lenvatinib versus Carboplatin and Paclitaxel as First-Line Therapy for Advanced or Recurrent Endometrial Cancer: A Markov Analysis. Gynecologic Oncology, 162, 249-255. https://doi.org/10.1016/j.ygyno.2021.05.038 |
| [22] | Lee, C.H., Shah, A.Y., Rasco, D., Rao, A., Taylor, M.H., Di Simone, C., Hsieh, J.J., Pinto, A., Shaffer, D.R., Girones, Sarrio, R., et al. (2021) Lenvatinib plus Pembrolizumab in Patients with Either Treatment-Naive or Previously Treated Metastatic Renal Cell Carcinoma (Study 111/KEYNOTE-146): A Phase 1b/2 Study. The Lancet Oncology, 22, 946-958. https://doi.org/10.1016/S1470-2045(21)00241-2 |
| [23] | Kai, M., Hikita, H., Kazuki, M., Tahata, Y., Shinkai, K., Doi, A., Ohkawa, K., Miyazaki, M., Ishida, H., Matsumoto, K., et al. (2024) Clinical Factors Associated with the Therapeutic Efficacy of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: A Multicenter Prospective Observational Study. PLOS ONE, 19, e0294590. https://doi.org/10.1371/journal.pone.0294590 |
| [24] | Yuan, L., Jia, G.D., Lv, X.F., Xie, S.Y., Guo, S.S., Lin, D.F., Liu, L.T., Luo, D.H., Li, Y.F., Deng, S.W., et al. (2023) Camrelizumab Combined with Apatinib in Patients with First-Line Platinum-Resistant or PD-1 Inhibitor Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Single-Arm, Phase 2 Trial. Nature Communications, 14, Article No. 4893. https://doi.org/10.1038/s41467-023-40402-x |
| [25] | Ding, X., Zhang, W.J., You, R., Zou, X., Wang, Z.Q., Ouyang, Y.F., Peng, L., Liu, Y.P., Duan, C.Y., Yang, Q., et al. (2023) Camrelizumab plus Apatinib in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 41, 2571-2582. https://doi.org/10.1200/JCO.22.01450 |
| [26] | Walle, T., Martinez Monge, R., Cerwenka, A., Ajona, D., Melero, I. and Lecanda, F (2018) Radiation Effects on Antitumor Immune Responses: Current Perspectives and Challenges. Therapeutic Advances in Medical Oncology, 10, 1-27. https://doi.org/10.1177/1758834017742575 |
| [27] | Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377. https://doi.org/10.1038/nature14292 |
| [28] | Seyedin, S.N., Schoenhals, J.E., Lee, D.A., Cortez, M.A., Wang, X., Niknam, S., Tang, C., Hong, D.S., Naing, A., Sharma, P., et al. (2015) Strategies for Combining Immunotherapy with Radiation for Anticancer Therapy. Immunotherapy, 7, 967-980. https://doi.org/10.2217/imt.15.65 |
| [29] | Chen, S.Y., Duan, X.T., Li, H.F., Peng, L., Wang, Z.Q., Xu, G.Q., Hua, Y.J., Zou, X., You, R., Ouyang, Y.F., et al. (2023) Efficacy of Sequential Chemoradiotherapy Combined with Toripalimab in De Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial. Cell Reports Medicine, 4, Article ID: 101279. https://doi.org/10.1016/j.xcrm.2023.101279 |
